StockNews.AI
FLGT
StockNews.AI
194 days

Fulgent to Announce Fourth Quarter and Full Year 2024 Financial Results on Friday, February 28, 2025

1. Fulgent Genetics will announce Q4 2024 results on February 28, 2025. 2. Management will host an investor conference call at 8:30 AM ET. 3. Fulgent is transitioning to a fully integrated precision medicine company. 4. Their therapeutic development focuses on advanced cancer treatment techniques. 5. The company aims to enhance drug efficacy through novel technologies.

3m saved
Insight
Article

FAQ

Why Neutral?

The upcoming earnings call may provide insights but is expected not to significantly affect price.

How important is it?

Earnings announcements typically influence stock prices, but current expectations are neutral.

Why Short Term?

The imminent announcement will have immediate implications on investor sentiment.

Related Companies

FLGT
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its fourth quarter and full year 2024 financial results before the market opens on Friday, February 28, 2025. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer questions. The call may be accessed through a live audio webcast on the Investor Relations section of the Company’s website, http://ir.fulgentgenetics.com. An audio replay will be available at the same location. About Fulgent Fulgent is a technology-based company with a well-established laboratory services business and a therapeutic development business. Fulgent’s laboratory services business, which was formerly referred to as the clinical diagnostic business, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Fulgent’s therapeutic development business is focused on developing drug candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The Company aims to transform from a genomic diagnostic business into a fully integrated precision medicine company.

Related News